Fly News Breaks for May 23, 2019
ITCI
May 23, 2019 | 07:22 EDT
Cantor Fitzgerald analyst Charles Duncan raised his price target for Intra-Cellular to $29 from $26 and reiterates an Overweight rating on the shares. Following due diligence, the analyst sees reduced regulatory and commercial risk for lumateperone in its lead indication schizophrenia.
News For ITCI From the Last 2 Days